Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.43 |
| ▸ | TTR | P02766 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5850794 | 1.00 | ALDH1A1 (0.44) | ALDH1A1MAPTKDM4EHPGDHSD17B10 | |
| SCHEMBL5853213 | 0.84 | PARP1 (0.48) | ALDH1A1MAPTKDM4EHPGDCYP1A2 | |
| SCHEMBL5853217 | 0.84 | PARP1 (0.48) | ALDH1A1MAPTKDM4EHPGDCYP1A2 | |
| SCHEMBL5851501 | 0.82 | APP (0.47) | ALDH1A1MAPTKDM4EHPGDHSD17B10 | |
| SCHEMBL5851498 | 0.82 | APP (0.47) | ALDH1A1MAPTKDM4EHPGDHSD17B10 | |
| SCHEMBL28700434 | 0.79 | MAPT (0.39) | ALDH1A1MAPTKDM4EHPGDHSD17B10 | |
| SCHEMBL1324190 | 0.77 | TUBB4A (0.48) | ALDH1A1MAPTKDM4EHPGDHSD17B10 | |
| SCHEMBL1323738 | 0.77 | TUBB4A (0.48) | ALDH1A1MAPTKDM4EHPGDHSD17B10 | |
| SCHEMBL12121400 | 0.77 | TUBB4A (0.48) | ALDH1A1MAPTKDM4EHPGDHSD17B10 | |
| SCHEMBL13646763 | 0.74 | CYP1A2 (0.50) | ALDH1A1HPGDHSD17B10CYP1A2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7153852-B2 | Indole compounds, process for producing the same and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-12-26 | — | — | US | disclosed |
| US-7098234-B2 | Indole derivatives, process for preparation of the same and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-08-29 | — | — | US | disclosed |
| US-20050004096-A1 | Indole derivatives, process for producing the same and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-01-06 | — | — | US | disclosed |
| CN-1179945-C | Indole derivatives, process for preparation of same and use thereof | СҰҩƷ��ҵ��ʽ���� | 2004-12-15 | — | — | CN | disclosed |
| US-20040180885-A1 | Indole derivatives, process for preparation of the same and use thereof | ONO PHARMACEUTICAL CO., LTD. | 2004-09-16 | — | — | US | disclosed |
| EP-1424325-A1 | INDOLE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-06-02 | — | — | EP | disclosed |
| US-6743793-B2 | DP RECEPTOR ANTAGONIST; PROSTAGLANDIN D | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-06-01 | — | — | US | disclosed |
| US-20030176400-A1 | Indole derivatives, process for preparation of the same and use thereof | ONO PHARMACEUTICALS CO., LTD. (JP) | 2003-09-18 | — | — | US | disclosed |
| CN-1427824-A | Indole derivatives, process for preparation of same and use thereof | ONO PHARMACEUTICAL CO (JP) | 2003-07-02 | — | — | CN | disclosed |
| EP-1262475-A1 | INDOLE DERIVATIVES, PROCESS FOR PREPARATION OF THE SAME AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-12-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176400-A1 | Indole derivatives, process for preparation of the same and use thereof | IDO1, KIT, ITCH | ALDH1A1 810/4885MAPT 617/4885KDM4E 2893/4885 |
| US-20050004096-A1 | Indole derivatives, process for producing the same and drugs containing the same as the active ingredient | IDO1, IDO2, PTGIR | ALDH1A1 477/4885MAPT 1213/4885KDM4E 2671/4885 |
| US-20040180885-A1 | Indole derivatives, process for preparation of the same and use thereof | IDO1, KIT, ITCH | ALDH1A1 810/4885MAPT 617/4885KDM4E 2893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.